Reference number : 172-2018-2019-Q3-899107, amendment number : 1, agreement type : C, recipient legal name : Kalgene Pharmaceuticals Inc., recipient country : CA, recipient province : QC, recipient city : Montreal|Montréal, recipient postal code : H4P 2R2, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : Development of a Biological Therapeutic Drug to Reverse Alzheimer's Disease, agreement title french : Développement d'un médicament thérapeutique biologique pour inverser la maladie d'Alzheimer, agreement number : 899107, agreement value : 350000.0, agreement start date : 2018-01-02, agreement end date : 2019-03-31, description english : KalGene and its NRC partners have identified a novel biological agent against amyloid-beta for Alzheimer’s disease. The IRAP project will support the late-stage development of the drug candidate.., description french : Développement d'un médicament thérapeutique biologique pour inverser la maladie d'Alzheimer, expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : This agreement has been amended 1 time(s). The total amended value is 68,000 dollars., additional information french : Cet accord a été modifié 1 fois La valeur totale des modifications est de   68 000 dollars., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada